Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Advanced Solid Tumors 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2mCRPC 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Fanconi Anemia, Complementation Group D1 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Adenocarcinoma 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

Alpelisib 4berzosertib 3Fulvestrant 3Everolimus 3parsaclisib 2Topotecan 2NVP-BKM120 2Cetuximab 2talazoparib 1sotorasib 1serabelisib 1ruxolitinib 1duvelisib 1dapagliflozin 1cobimetinib 1ceralasertib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Letrozole 1Irinotecan 1Goserelin 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Sensory and Autonomic Neuropathies × talazoparib × Clear all
NCT03565991 2023-09-25

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Pfizer

Phase 2 Terminated
202 enrolled 31 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡